CTLA-4 or PD-1/PD-L1 blockade is associated with increased survival in melanoma, renal cell cancer, non-small cell lung cancer, bladder cancer, and Hodgkins lymphoma [7]. The gene discussed is PDCD1; the disease is urinary bladder carcinoma.